Not So Different: A Podcast from The Center for Biosimilars

S6 Ep8: Biosimilars Rheumatology Roundup for April 2023—Podcast Edition

Listen

Description


Biosimilars Check In: Vegzelma Launch, BLA Acceptances, China Approval



FDA Issues Another CRL for Alvotech’s Adalimumab Biosimilar



Multiple Infliximab Biosimilar Switches Appear Safe, Effective for Patients With IBD



Study on Nonmedical Switching for Adalimumab Biosimilars Warns About Nocebo Effect



Spherix Global Insights: Despite High Awareness, Provider Comfort With Adalimumab Biosimilars Is Low



Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars



Study Reveals Factors That Dissuade Commercial Plans From Covering Biosimilars